CYP3A5*3 and CYP3A4*1B allele distribution and genotype combinations: Differences between Spaniards and Central Americans

Therapeutic Drug Monitoring

Volumn 29, Issue 4, 2007, Pages 412-416

  Sinues, Blanca ^a,e   Vicente, Jorge ^a   Fanlo, Ana ^a   Vasquez, Patricia ^b   Medina, Juan Carlos ^c   Mayayo, Esteban ^d   Conde, Blanca ^a   Arenaz, Izaskun ^a   Martinez Jarreta, Begoña ^a  

^a UNIVERSITY OF ZARAGOZA   (Spain)

^b University José Matías Delgado Delgado   (El Salvador)

^c UNIVERSITY OF LEÓN   (Spain)

^d HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^e UNIVERSITY OF ZARAGOZA   (Spain)

Author keywords

Central Americans; CYP3A; CYP3A4*1B; CYP3A5*3; Spaniards

Indexed keywords

CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYP3A4 PROTEIN, HUMAN; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450; CYTOCHROME P450 3A; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; EL SALVADOR; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; HUMAN; MALE; MUTATIONAL ANALYSIS; NICARAGUA; NORMAL HUMAN; POPULATION GENETICS; PREVALENCE; PRIORITY JOURNAL; RACE DIFFERENCE; SPAIN; ADOLESCENT; ALLELE; AMERICAN INDIAN; CAUCASIAN; COMPARATIVE STUDY; GENE LINKAGE DISEQUILIBRIUM; GENETICS; GENOTYPE; METABOLISM; MIDDLE AGED;

ADOLESCENT; ADULT; ALLELES; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; EL SALVADOR; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; INDIANS, CENTRAL AMERICAN; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; NICARAGUA; POLYMORPHISM, GENETIC; SPAIN;

EID: 34547665041     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31811f390a     Document Type: Article

References (38)

1. Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in the human liver cytochrome P-450 enzyme involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther. 1994;270:414-423.
2. de Wildt SN, Kearns GL, Leeder JS, et al. Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet. 1999;37:485-505.
3. Guengerich FP. Oxidation of toxic and carcinogenic chemicals by human cytochrome P450 enzymes. Chem Res Toxicol. 1991;4:391-407.
4. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001;27:383-391.
5. Lin Y, Dowling A, Quigley S, et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol. 2002;62:162-172.
6. Ozdemir V, Kalowa W, Tang BK, et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics. 2000;10:373-388.
7. Gonzalez FJ, Schmid BJ, Umeno M, et al. Human P450PCN1: sequence, chromosome localizations and direct evidence through cDNA expression that P450PCN1 in nifedipine oxidase. DNA. 1988;7:79-86.
8. Rebbeck TR, Jaffe JM, Walker AH, et al. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst. 1998;90:1225-1229.
9. Paris PL, Kupelian PA, Hall JM, et al. Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol Biomarker Prev. 1999;8:901-905.
10. Tayeb MT, Clark C, Sharp L, et al. CYP3A4 promoter variant is associated with prostate cancer risk in men with benign prostate hyperplasia. Oncol Rep. 2002;9:653-655.
11. Felix CA, Walker AH, Lange BJ, et al. Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci USA. 1988;95:13176-13181.
12. Amirimani B, Walker AH, Weber BL, et al. Response: re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. Cancer Inst. 1999;91:1588-1590.
13. Ando Y, Tateishi T, Sekido Y, et al. Re: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4 [Letter; comment]. J Natl Cancer Inst. 1999;91:1587-1590.
14. Rodriguez-Antona C, Sayi JG, Gustafsson LL, et al. Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant C YP3A4 alleles. Biochem Biophys Res Commun. 2005;338:299-305.
15. Garcia-Martin E, Matinez C, Pizarro RM, et al. CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity. Clin Pharmacol Ther. 2002;71:196-204.
16. von Ahsen N, Richter M, Grupp C, et al. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3-A4-V allele) on dose-adjusted cyclosporine A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem. 2001;47:1048-1052.
17. Ball SE, Scatina J, Kao J, et al. Population distribution and effects on drug metabolism of a genetic variant in the 5# promoter region of CYP3A4. Clin Pharmacol Ther. 1999;66:288-294.
18. Zeigler-Johnson C, Friebel T, Walker AH, et al. CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer. Cancer Res. 2004;64:8461-8467.
19. Kittles RA, Chen W, Panguluri RK, et al. CYP3A4-V and prostate cancer in African Americans: causal or confounding association because of population stratification? Human Genet. 2002;110:553-560.
20. Plummer SJ, Conti DV, Paris PL, et al. CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2003;12:928-932.
21. Aplenc R, Glatfelter W, Han P, et al. CYP3A genotypes and treatment response in paediatric acute lymphoblastic leukaemia. Br J Haematol. 2003;122:240-244.
22. He P, Court MH, Greenblatt DJ, et al. Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo. Clin Pharmacol Ther. 2005;77:373-387.
23. Kadlubar FF, Berkowitz GS, Delongchamp RR, et al. The CYP3A4*1B variant is related to the onset of puberty, a known risk factor for the development of breast cancer. Cancer Epidemiol Biomarker Prev. 2003;12:327-331.
24. Westlind-Jonhsson A, Malmebo S, Johansson A, et al. Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Dispos. 2003;31:755-761.
25. Gervasini G, Vizcaino S, Gasiba C, et al. Differences in CYP3A5*3 genotype distribution and combinations with other polymorphisms between Spaniards and other Caucasian populations. Ther Drug Monit. 2005;27:819-821.
26. Dally H, Bartsch H, Jager B, et al. Genotype relationships in the CYP3A locus in Caucasians. Cancer Lett. 2004;207:95-99.
27. Lucotte G, Gerard N, Mercier G. North African genes in Iberia studied by Y-chromosome DNA haplotype 5. Human Biol. 2001;73:763-769.
28. Haufroid V, Mourad M, van Kerckhove V, et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirement and trough blood levels in stable renal transplant patients. Pharmacogenetics. 2004;14:147-154.
29. Wong M, Balleine RL, Collins M, et al. CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy. Clin Pharmacol Ther. 2004;75:529-538.
30. Katz DA, Grimm DR, Cassar SC, et al. CYP3A5 genotype has a dosedependent effect on ABT-733 plasma levels. Clin Pharmacol Ther. 2004;75:516-528.
31. Lamba JK, Lin YS, Schuetz EG, et al. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Devil Rev. 2002;54:1271-1294.
32. Schirmer M, Toliat MR, Haberl M, et al. Genetic signature consistent with selection against the CYP3A4*1B allele in non-African populations. Pharmacogenetics and Genomics. 2006;16:59-71.
33. Wandel C, Witte JS, Hall JM, et al. CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B 5′-promoter region polymorphism. Clin Pharmacol Ther. 2000;68:82-91.
34. Dally H, Edler L, Jager B, et al. The CYP3A4*1B allele increases risk for small cell lung cancer: effect of gender and smoking dose. Pharmacogenetics. 2003;13:607-618.
35. Balram C, Zhou Q, Cheung YB, et al. CYP3A5*3 and *6 single nucleotide polymorphisms in three distinct Asian populations. Eur J Clin Pharmacol. 2003;59:123-126.
36. Fukuen S, Fukuda T, Maune H, et al. Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population. Pharmacogenetics. 2002;12:331-334.
37. Cavaco I, Gil JP, Gil-Berglund E, et al. CYP3A4 and MDR1 alleles in a Portuguese population. Clin Chem Lab Med. 2003;41:1345-1350.
38. Chowbay B, Zhou S, Lee EJ. An interethnic comparison of polymorphisms of the genes encoding drug-metabolizing enzymes and drug transporters: experience in Singapore. Drug Metab Rev. 2005;37:327-378.